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Introduction
Background: 
– 41.8% of pregnancies are affected by anemia, and the majority 
(75%) of these cases are due to iron-deficiency anemia1,2
– Anemia during pregnancy can lead to numerous complications 
including preterm birth, low birthweight, and poorer fetal
neurological outcomes, and cesarean section3
– Favorable maternal and fetal outcomes have been shown 
following IV and oral iron supplementation 
Rationale:
• Yet, currently there is no preferred administration of iron 




• Compare maternal and fetal outcomes following IV and oral iron 
supplementation for iron deficiency anemia during pregnancy
Research Question:
• Does IV iron supplementation for anemia during pregnancy lead to 
superior maternal and fetal outcomes compared to oral iron 
supplementation? 
Hypothesis:
• IV iron supplementation will increase maternal hemoglobin more 
rapidly and result in fewer side effects compared to oral iron 
supplementation. 
Approach
• Systematic Review & Meta-Analysis
• Searched Medline, OVID, Scopus, 
ClinicalTrials.gov and Cochrane
• Included all RCTs studying IV vs PO iron for 
treatment of iron deficiency anemia during 
pregnancy
• Intervention group: IV iron
• Comparison group: PO iron
• Fetal outcomes: 
– Birthweight (g)
– Hgb and ferritin 
– Gestational Age at Delivery 
• Maternal Outcomes: 
– Hgb and Ferritin during pregnancy and 
delivery 
– Patient Reported Outcomes 
– Adverse Reactions (GI distress, anaphylactic, 
injection site disorder)
• Analysis 
– Standardized mean difference (SMD) and 
relative risk (RR) using Review Manger 5.3




searching or other 
sources
(n=576)











• No maternal/fetal 
outcomes (n=17)




• Could not obtain 
text (n=1)
• Duplicate articles 
(n=6)




Patient & Study Characteristics 
• Included 11 randomized controlled studies 5-15
– IV group: 1621 women; mean age: 24.9 years
– Oral group: 1640 women; mean age: 24.6 years
• Iron deficiency anemia determined by:
– hemoglobin<11.5 g/dL 9-11,14-15 or <9.0g/dL, 5-8,12-13
– serum ferritin levels
• Select exclusion criteria in studies: 
– Other hematological diseases (excluding iron-deficiency 
anemia)6,9,14
– Severe liver disease 4,9,11
Results
Results & Complications 
• Fetal birthweight and serum 
ferritin was 
significantly(P<0.05) higher 
in the IV group 
• PO group experienced GI 
distress at significantly higher 
rate (P<0.05)
• IV group: 11 (0.67%) women 
with an injection site 
disorder, 15 (0.93%) 
experienced a fever
• No significant difference in 
blood transfusions or 
cesarean deliveries 
Table 1. Select Maternal & Fetal Outcomes, Hgb: 
hemoglobin, GI: gastrointestinal SMD: standard 
mean difference, RR: relative risk, P: P-Value
Results
Figure 1. Forest plot of maternal hemoglobin (Hgb) at 
term/delivery
• Intravenous iron supplementation for iron deficiency 
anemia during pregnancy results in higher neonatal 
birthweight, higher maternal hemoglobin levels, and 
minimal adverse effects
• Future studies are needed to investigate the effect of IV 
iron on functional maternal outcomes and the cost-




• Thank you to Dr. Burd and Dr. Boelig for 
all of their guidance.
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